BCR-ABL-negative Chronic Myeloid Leukemia

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Specialties Hematology
Oncology

Date 2010 Apr 29

PMID 20425354

Citations 2

Authors

Sonja Burgstaller

Andreas Reiter

Nicholas C P Cross

Affiliations

Soon will be listed here.

Abstract

Constitutive activation of protein tyrosine kinases plays a central role in the pathogenesis of myeloproliferative disorders, including BCR-ABL-negative chronic myeloid leukemia. Current research is focused on elucidating the full spectrum of causative mutations in this rare, heterogeneous disease. Activated tyrosine kinases are excellent targets for signal transduction therapy, and an accurate diagnosis including morphology, karyotyping, and molecular genetics will become increasingly important to direct individualized treatment. In addition, new molecular findings need to be incorporated into disease classification systems.

Citing Articles

The double face of Morgana in tumorigenesis.

Brancaccio M, Rocca S, Secli L, Busso E, Fusella F Oncotarget. 2015; 6(40):42603-12.

PMID: 26460959 PMC: 4767456. DOI: 10.18632/oncotarget.6058.

Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.

Zoi K, Cross N Int J Hematol. 2014; 101(3):229-42.

PMID: 25212680 DOI: 10.1007/s12185-014-1670-3.

References

Morerio C, Acquila M, Rosanda C, Rapella A, Dufour C, Locatelli F . HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res. 2004; 64(8):2649-51. DOI: 10.1158/0008-5472.can-03-4026. View

Chase A, Huntly B, Cross N . Cytogenetics of chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2001; 14(3):553-71. DOI: 10.1053/beha.2001.0154. View

Vardiman J, Lee Harris N, Brunning R . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100(7):2292-302. DOI: 10.1182/blood-2002-04-1199. View

Stover E, Chen J, Folens C, Lee B, Mentens N, Marynen P . Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci U S A. 2006; 103(21):8078-83. PMC: 1472432. DOI: 10.1073/pnas.0601192103. View

Lacronique V, Boureux A, Valle V, Poirel H, Quang C, Mauchauffe M . A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997; 278(5341):1309-12. DOI: 10.1126/science.278.5341.1309. View

Guasch G, Popovici C, Mugneret F, Chaffanet M, Pontarotti P, Birnbaum D . Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood. 2002; 101(1):286-8. DOI: 10.1182/blood-2002-02-0577. View

Vu H, Xinh P, Masuda M, Motoji T, Toyoda A, Sakaki Y . FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia. 2006; 20(8):1414-21. DOI: 10.1038/sj.leu.2404266. View

Roumiantsev S, Krause D, Neumann C, Dimitri C, Asiedu F, Cross N . Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell. 2004; 5(3):287-98. DOI: 10.1016/s1535-6108(04)00053-4. View

Griffin J, Leung J, Bruner R, Caligiuri M, Briesewitz R . Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A. 2003; 100(13):7830-5. PMC: 164673. DOI: 10.1073/pnas.0932698100. View

10.

Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal J, Verstovsek S . JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005; 106(10):3370-3. PMC: 1895065. DOI: 10.1182/blood-2005-05-1800. View

11.

Jones A, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L . Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005; 106(6):2162-8. DOI: 10.1182/blood-2005-03-1320. View

12.

Wilkinson K, Velloso E, Lopes L, Lee C, Aster J, Shipp M . Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood. 2003; 102(12):4187-90. DOI: 10.1182/blood-2003-04-1150. View

13.

Rosati R, La Starza R, Luciano L, Gorello P, Matteucci C, Pierini V . TPM3/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukemia. Leukemia. 2006; 20(9):1623-4. DOI: 10.1038/sj.leu.2404307. View

14.

Kurzrock R, Bueso-Ramos C, Kantarjian H, Freireich E, Tucker S, Siciliano M . BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol. 2001; 19(11):2915-26. DOI: 10.1200/JCO.2001.19.11.2915. View

15.

Vannier J, Bizet M, Bastard C, Bernard A, Ducastelle T, Tron P . Simultaneous occurrence of a T-cell lymphoma and a chronic myelogenous leukemia with an unusual karyotype. Leuk Res. 1984; 8(4):647-57. DOI: 10.1016/0145-2126(84)90013-4. View

16.

Gu T, Goss V, Reeves C, Popova L, Nardone J, MacNeill J . Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood. 2006; 108(13):4202-4. DOI: 10.1182/blood-2006-06-026666. View

17.

David M, Cross N, Burgstaller S, Chase A, Curtis C, Dang R . Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood. 2006; 109(1):61-4. DOI: 10.1182/blood-2006-05-024828. View

18.

Cools J, DeAngelo D, Gotlib J, Stover E, Legare R, Cortes J . A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348(13):1201-14. DOI: 10.1056/NEJMoa025217. View

19.

Vizmanos J, Hernandez R, Vidal M, Larrayoz M, Odero M, Marin J . Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases. Hematol J. 2004; 5(6):534-7. DOI: 10.1038/sj.thj.6200561. View

20.

Onida F, Ball G, Kantarjian H, Smith T, Glassman A, Albitar M . Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer. 2002; 95(8):1673-84. DOI: 10.1002/cncr.10832. View